Cingulate Inc. (NASDAQ:CINGW – Get Free Report) was the target of a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 1 shares, a decline of 99.9% from the September 30th total of 864 shares. Based on an average trading volume of 22,414 shares, the short-interest ratio is presently 0.0 days.
Cingulate Stock Down 55.5%
Shares of CINGW stock opened at $0.00 on Tuesday. Cingulate has a 1-year low of $0.00 and a 1-year high of $0.12. The company has a 50-day moving average of $0.01 and a two-hundred day moving average of $0.03.
Cingulate Company Profile
Cingulate Inc is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders. The company is focused on its Precision Timed Release (PTR) drug-delivery platform, which is designed to deliver multiple doses of medication at specific times from a single dosage form.
Cingulate’s lead program, CTx-1301, is an investigational extended-release formulation of dexmethylphenidate intended to treat attention-deficit/hyperactivity disorder (ADHD). The company has also pursued CTx-1302, an investigational treatment candidate for anxiety disorders.
See Also
- Five stocks we like better than Cingulate
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.
